Feasibility and safety of a standardized low-dose thrombolytic therapy for right-sided mechanical prosthetic valve thrombosis in adult congenital heart disease Authors: Naoto Shingu, Tomoyasu Suenaga, Ayako Ishikita, Soshun Asakawa, Masahiko Umei, Akiko Nishizaki, Takamori Kakino, Ichiro Sakamoto, Eiko Terashi, Kenichiro Yamamura, Tomoki Ushijima, Kunihiko Joo, Yusuke Ando, Hiromichi Sonoda, Akira Shiose, Kohtaro Abe Published: 2026 ABSTRACT BackgroundMechanical valve thrombosis is a serious complication in adults with congenital heart disease (ACHD). Although low-dose thrombolytic therapy has emerged as a potential alternative to surgery, evidence in ACHD patients with right-sided mechanical valve thrombosis remains limited. We evaluated the feasibility and safety of a standardized low-dose thrombolytic protocol in this population.MethodsWe retrospectively reviewed consecutive ACHD patients with right-sided mechanical valve thrombosis treated at our institution between 2022 and 2025. Diagnosis was based on fluoroscopic, echocardiographic, and computed tomography findings. All patients received a standardized low-dose alteplase regimen (25 mg over 6 h). Treatment efficacy was assessed primarily by restoration of prosthetic leaflet mobility on fluoroscopy.ResultsFive patients were included: four with mechanical pulmonary valves and one with a mechanical tricuspid valve. Thrombosis occurred a median of 2.3 years after valve replacement, and all patients had subtherapeutic anticoagulation (international normalized ratio <2.0) during the preceding month. At presentation, four patients were in New York Heart Association functional class II and one in class III. Following a median of 5 days of thrombolytic therapy, complete restoration of prosthetic leaflet mobility was achieved in all patients. No major bleeding or thromboembolic complications occurred. During a median follow-up of 0.7 years, no recurrent valve thrombosis was observed.ConclusionsStandardized low-dose thrombolytic therapy was safe and feasible in this case series and may provide a non-surgical treatment option for ACHD patients with right-sided mechanical valve thrombosis. Introduction Adults with congenital heart disease (ACHD) often have complex anatomy, multiple comorbidities, and a history of repeated sternotomies. Right-sided valvular disease is common in ACHD and repeat intervention for valve dysfunction is frequently required during long-term follow-up. As a result, perioperative risk associated with reoperation in cardiac surgery increases with the number of prior sternotomies [1,2]. To reduce the need for repeated cardiac surgery, mechanical valves, which offer greater durability than bioprosthetic valves, may be considered for right-sided valve replacement. However, due to lower flow velocity and pressure conditions in the right-sided circulation, with a greater propensity for blood stasis, the incidence of mechanical valve thrombosis in the pulmonary position is higher than that in the aortic position. The incidence of mechanical valve thrombosis has been estimated to be 1.7% per patient-year for pulmonary valve prostheses, compared with 0–0.6% per patient-year for aortic valve prostheses [3]. Thrombolytic therapy for mechanical valve thrombosis has gained attention as a non-invasive and effective treatment option and has been primarily reported in left-sided mechanical valves [4]. For right-sided mechanical valve thrombosis, the 2025 ESC/EACTS guidelines recommend thrombolytic therapy as a treatment option, particularly in patients with right-sided mechanical valves at high risk for surgical reintervention [5]. In the HATTUSHA study, a low-dose and slow-infusion protocol using t-PA 25 mg administered over 6 h achieved a high success rate in patients with thrombosed aortic, mitral, and tricuspid mechanical valves in non-ACHD patients [4]. However, data on standardized thrombolytic protocols in patients with ACHD, particularly those with multiple prior sternotomies, are lacking. In addition, non-surgical therapeutic strategies aimed at avoiding high-risk reoperation have not been fully evaluated. In this context, we applied a standardized low-dose alteplase thrombolytic protocol to a series of ACHD patients with right-sided mechanical valve thrombosis to evaluate its feasibility and safety. Furthermore, we explored thrombolysis as a non-surgical rescue strategy to avoid high-risk reoperation in this population. Methods Patient population We retrospectively reviewed 42 ACHD patients who underwent a total of 50 right-sided mechanical valve replacements including 41 pulmonary valve replacements and 9 tricuspid valve replacements among all right-sided valve replacement procedures performed at our institution, including 209 pulmonary valve replacements and 68 tricuspid valve replacements. These mechanical valve replacement procedures included in this study were performed between September 2016 and June 2024. At our institution, right-sided mechanical valves were preferentially used in patients at high risk for repeat sternotomy, those requiring early reintervention after bioprosthetic valve replacement, and those already requiring strict anticoagulation because of concomitant left-sided mechanical valves. Mechanical prosthetic valve thrombosis was suspected based on new clinical symptoms, changes in prosthetic valve sounds, or increased transvalvular velocity on routine echocardiography. Cinefluoroscopy and contrast-enhanced cardiac CT were not performed routinely but were obtained when prosthetic valve thrombosis was clinically suspected. The diagnosis was based on an integrated assessment of subtherapeutic anticoagulation, impaired leaflet mobility on echocardiography or cinefluoroscopy, and a low-attenuation lesion associated with the prosthetic valve on cardiac CT. When technically feasible, CT attenuation values were measured, with values < 145 HU considered supportive of thrombus rather than pannus based on previously reported criteria [6]. Blood cultures were obtained when infective endocarditis was suspected based on clinical findings such as fever or elevated inflammatory markers. As thrombolytic therapy for mechanical valve thrombosis is an off-label treatment in Japan, this treatment was approved by the Ethics Committee of Kyushu University Hospital. Written informed consent for thrombolytic therapy was obtained prior to treatment. Clinical data were retrospectively collected from the electronic medical records by two authors (N.S. and T.S.). Thrombolytic therapy Thrombolytic therapy was performed using a protocol modified from a previously published regimen (Fig. 1) [4]. Before initiation of therapy, all patients underwent head CT and fecal occult blood testing to exclude active bleeding, including intracranial or gastrointestinal hemorrhage. Warfarin therapy was discontinued, and anticoagulation was transitioned to continuous intravenous unfractionated heparin (UFH).Fig. 1Protocol for low-dose thrombolytic therapy.Unfractionated heparin (UFH) was discontinued before thrombolytic therapy. Thrombolytic therapy was initiated once the activated partial thromboplastin time (APTT) was <50 s. Alteplase (25 mg) was infused over 6 h. Thrombolytic therapy was discontinued if stroke or major bleeding was suspected. UFH was resumed 1 h after completion of thrombolytic therapy. Cinefluoroscopy was performed daily to assess prosthetic valve leaflet mobility. The low-dose alteplase protocol was repeated on the following day only if leaflet mobility remained impaired. Dobutamine was administered continuously throughout the overall treatment period, including both alteplase and UFH therapy. Protocol for low-dose thrombolytic therapy. Unfractionated heparin (UFH) was discontinued before thrombolytic therapy. Thrombolytic therapy was initiated once the activated partial thromboplastin time (APTT) was <50 s. Alteplase (25 mg) was infused over 6 h. Thrombolytic therapy was discontinued if stroke or major bleeding was suspected. UFH was resumed 1 h after completion of thrombolytic therapy. Cinefluoroscopy was performed daily to assess prosthetic valve leaflet mobility. The low-dose alteplase protocol was repeated on the following day only if leaflet mobility remained impaired. Dobutamine was administered continuously throughout the overall treatment period, including both alteplase and UFH therapy. On the day of thrombolytic therapy, resolution of the anticoagulant effects of warfarin was confirmed. UFH infusion was temporarily discontinued, and alteplase was administered after confirming that the activated partial thromboplastin time (APTT) was <50 s. Alteplase was administered at a fixed dose of 25 mg as a 6-h intravenous infusion. UFH infusion was resumed 1 h after completion of alteplase infusion. During anticoagulation and thrombolytic therapy, dobutamine was administered concomitantly at a dose of 2.0 μg/kg/min to increase transvalvular flow velocity. Fluoroscopic evaluation of prosthetic valve leaflet motion was performed daily. If leaflet mobility remained impaired, the same low-dose alteplase protocol was repeated on the following day, for up to five consecutive days, with UFH administered between alteplase infusions. Thrombolytic therapy was continued according to the planned protocol for up to five days or discontinued earlier when complete restoration of leaflet mobility was confirmed. Thrombolytic therapy was immediately discontinued if patients developed headache, neurological symptoms, or any signs of overt bleeding. Bleeding complications were assessed according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH) [7]. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical organ, bleeding causing a decrease in hemoglobin level of 2 g/dL or more, or bleeding requiring transfusion of two or more units of whole blood or red cells. All other bleeding events were classified as minor bleeding. Statistical analysis Continuous variables are presented as median (interquartile range [IQR]), and categorical variables are presented as number and percentage. Log B-type natriuretic peptide (BNP) values were compared using a paired t-test. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism 10 (GraphPad Software, San Diego, CA, USA). Ethics statement This study protocol was approved by the Ethics Committee of Kyushu University Hospital on May 18, 2026 (approval No.25294). For this retrospective study, an opt-out approach was used in accordance with institutional guidelines. Information about the study was publicly disclosed, and patients were given the opportunity to decline participation. The study was conducted in accordance with the Declaration of Helsinki, and the privacy rights of the participants were protected. Results Patient characteristics Five consecutive patients with ACHD who developed right-sided mechanical valve thrombosis were treated with low-dose thrombolytic therapy. Baseline characteristics are summarized in Table 1. The underlying congenital heart diseases included pulmonary atresia with intact ventricular septum (PA/IVS), double outlet right ventricle with pulmonary atresia and ventricular septal defect (DORV/PA/VSD), tetralogy of Fallot (TOF), pulmonary atresia with ventricular septal defect (PA/VSD), and severe tricuspid regurgitation secondary to perioperative right ventricular infarction following atrial and ventricular septal defect closure.Table 1Baseline characteristics of the five patients.Table 1Case 1Case 2Case 3Case 4Case 5Age, y3340222433SexFemaleFemaleMaleMaleFemaleBMI, kg/m234.225.318.522.718.0Original CHDPA/IVSDORV, PA, VSDASD, VSDTOFPA/VSDPrevious sternotomies, n46333Duration from mechanical valve implantation, y2.34.70.12.40.6Mechanical valve LocationAV, PVAV, PVTVPVPV Thrombosed valvePVPVTVPVPV ModelOn-X #19SJM Regent #19On-X #25/33SJM Regent #21SJM Regent #21RhythmAsVpSinusApVsSinusSinusNYHAⅢⅡⅡⅡⅡChief complaintDyspneaDyspneaAsymptomaticAsymptomaticAsymptomaticComorbidityDM, ObesityCKD, ScoliosisAnemiaBicuspid AVAnemia, ScoliosisThrombophiliaNoneNoneNoneNoneNoneLaboratory data Hemoglobin, g/dL15.315.012.115.88.4 eGFR, mL/min/1.73m267.142.796.7108.381.5 PT-INR1.932.012.31a1.581.91 D-dimer, μg/mL< 0.5< 0.51.9< 0.5< 0.5MRI RVEF, %45.031.210.239.332.3 RVEDVi, ml/m232.757.8270.5108.9134.1 RVESVi, ml/m218.039.8242.866.090.8 LVEF, %45.153.053.453.857.9 LVEDVi, ml/m287.949.756.285.585.8 LVESVi, ml/m248.223.426.239.436.1Risk Score EuroSCORE Ⅱ, %5.214.42.32.75.4Warfarin dose, mg/day3.53.02.55.52.25Aspirin dose, mg/dayNoneNone100 mgNoneNoneaAnticoagulation therapy after tricuspid valve replacement consisted of initial unfractionated heparin bridging (target APTT: 55–70 s) followed by warfarin therapy. AV, aortic valve; ApVs, atrial pacing–ventricular sensing; AsVp, atrial sensing–ventricular pacing; ASD, atrial septal defect; BMI, body mass index; CHD, congenital heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; DORV, double outlet right ventricle; eGFR, estimated glomerular filtration rate; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; LVEDVi, left ventricular end-diastolic volume index; LVESVi, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PA/IVS, pulmonary atresia with intact ventricular septum; PA/VSD, pulmonary atresia with ventricular septal defect; PT-INR, prothrombin time–international normalized ratio; PV, pulmonary valve; RVEDVi, right ventricular end-diastolic volume index; RVESVi, right ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; TOF, tetralogy of Fallot; TV, tricuspid valve; VSD, ventricular septal defect. Table 1Baseline characteristics of the five patients.Table 1Case 1Case 2Case 3Case 4Case 5Age, y3340222433SexFemaleFemaleMaleMaleFemaleBMI, kg/m234.225.318.522.718.0Original CHDPA/IVSDORV, PA, VSDASD, VSDTOFPA/VSDPrevious sternotomies, n46333Duration from mechanical valve implantation, y2.34.70.12.40.6Mechanical valve LocationAV, PVAV, PVTVPVPV Thrombosed valvePVPVTVPVPV ModelOn-X #19SJM Regent #19On-X #25/33SJM Regent #21SJM Regent #21RhythmAsVpSinusApVsSinusSinusNYHAⅢⅡⅡⅡⅡChief complaintDyspneaDyspneaAsymptomaticAsymptomaticAsymptomaticComorbidityDM, ObesityCKD, ScoliosisAnemiaBicuspid AVAnemia, ScoliosisThrombophiliaNoneNoneNoneNoneNoneLaboratory data Hemoglobin, g/dL15.315.012.115.88.4 eGFR, mL/min/1.73m267.142.796.7108.381.5 PT-INR1.932.012.31a1.581.91 D-dimer, μg/mL< 0.5< 0.51.9< 0.5< 0.5MRI RVEF, %45.031.210.239.332.3 RVEDVi, ml/m232.757.8270.5108.9134.1 RVESVi, ml/m218.039.8242.866.090.8 LVEF, %45.153.053.453.857.9 LVEDVi, ml/m287.949.756.285.585.8 LVESVi, ml/m248.223.426.239.436.1Risk Score EuroSCORE Ⅱ, %5.214.42.32.75.4Warfarin dose, mg/day3.53.02.55.52.25Aspirin dose, mg/dayNoneNone100 mgNoneNoneaAnticoagulation therapy after tricuspid valve replacement consisted of initial unfractionated heparin bridging (target APTT: 55–70 s) followed by warfarin therapy. AV, aortic valve; ApVs, atrial pacing–ventricular sensing; AsVp, atrial sensing–ventricular pacing; ASD, atrial septal defect; BMI, body mass index; CHD, congenital heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; DORV, double outlet right ventricle; eGFR, estimated glomerular filtration rate; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; LVEDVi, left ventricular end-diastolic volume index; LVESVi, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PA/IVS, pulmonary atresia with intact ventricular septum; PA/VSD, pulmonary atresia with ventricular septal defect; PT-INR, prothrombin time–international normalized ratio; PV, pulmonary valve; RVEDVi, right ventricular end-diastolic volume index; RVESVi, right ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; TOF, tetralogy of Fallot; TV, tricuspid valve; VSD, ventricular septal defect. Baseline characteristics of the five patients. Anticoagulation therapy after tricuspid valve replacement consisted of initial unfractionated heparin bridging (target APTT: 55–70 s) followed by warfarin therapy. AV, aortic valve; ApVs, atrial pacing–ventricular sensing; AsVp, atrial sensing–ventricular pacing; ASD, atrial septal defect; BMI, body mass index; CHD, congenital heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; DORV, double outlet right ventricle; eGFR, estimated glomerular filtration rate; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; LVEDVi, left ventricular end-diastolic volume index; LVESVi, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PA/IVS, pulmonary atresia with intact ventricular septum; PA/VSD, pulmonary atresia with ventricular septal defect; PT-INR, prothrombin time–international normalized ratio; PV, pulmonary valve; RVEDVi, right ventricular end-diastolic volume index; RVESVi, right ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; TOF, tetralogy of Fallot; TV, tricuspid valve; VSD, ventricular septal defect. The median age at the onset of thrombosis was 33 (IQR 23-37) years, and the median number of prior sternotomies was 3 (IQR 3-5). Mechanical valve thrombosis occurred at a median of 2.3 (IQR 0.4-3.6) years after valve replacement. At presentation, four patients were classified as New York Heart Association (NYHA) functional class II and one as class III. On cardiac magnetic resonance imaging, the median right ventricular ejection fraction was 32.3 (IQR 25.2-42.2) %, and the median right ventricular end-diastolic volume index was 66.0 (IQR 28.9-166.8) mL/m2. The diagnosis was prompted by dyspnea in two patients, routine outpatient echocardiography in two, and cardiac catheterization in one. Blood cultures were obtained in two patients with fever or elevated inflammatory markers and were negative in both. All patients were receiving warfarin therapy; however, subtherapeutic anticoagulation (INR <2.0) was documented in all patients during the month preceding thrombosis. Subtherapeutic anticoagulation persisted for more than two months in three of five patients. No patients had atrial fibrillation or known thrombophilic disorders. Cinefluoroscopic evaluation demonstrated reduced leaflet mobility in all cases. Contrast-enhanced CT revealed periprosthetic low-attenuation lesions suggestive of thrombus in four patients, with a median maximal transverse diameter of 6.0 (IQR 5.3-7.7) mm. Attenuation values were measurable in four patients and were <145 HU, consistent with thrombus rather than pannus. In Case 1, the pacemaker was implanted with epicardial leads. In Case 3, the pacemaker had transvenous leads, with no evidence of lead-associated thrombosis. Treatment outcomes All patients achieved normalization of prosthetic valve leaflet mobility following low-dose thrombolytic therapy. Improvement in prosthetic leaflet mobility was generally observed within the first 1–2 days after initiation of thrombolytic therapy, and complete restoration was achieved between Day 3 and Day 5 (Day 3 in Case 3 and 5, Day 4 in Case 2 and 4, and Day 5 in Case 1) (Supplementary Video 1). In Case 3, prosthetic valve thrombosis recurred after initial restoration of the leaflet mobility during a period of subtherapeutic anticoagulation, requiring an additional 5-day course of the same thrombolytic therapy. The median duration of therapy was 5 (IQR 5-7) days. Reductions were observed in transprosthetic pressure gradients on echocardiography and thrombus-related findings on CT (Table 2, Fig. 2). The degree of prosthetic valve regurgitation also improved following restoration of prosthetic leaflet mobility in all patients (Table 2). Median BNP decreased from 112.0 (IQR 46.5–179.3) pg/mL before treatment to 67.3 (IQR 33.0–92.6) pg/mL after treatment, with a significant reduction in log BNP values (median 2.0 to 1.8, p < 0.05) (Fig. 3).Table 2Imaging Findings of the five patients.Table 2Case 1Case 2Case 3Case 4Case 5Thrombosed valvePVPVTVPVPVModelOn-X #19SJM Regent #19On-X #25/33SJM Regent #21SJM Regent #21Echocardiogram findings at thrombosed valveOn admission Peak Velocity, m/s1.43.31.93.53.5 Peak pressure gradient, mmHg7.744.014.650.048.0 Mean pressure gradient, mmHg3.422.08.629.226.0 Regurgitationtrivialmild-moderatemild-moderatemildmildAfter thrombolysis Peak Velocity, m/s0.81.81.32.61.3 Peak pressure gradient, mmHg2.813.06.8266.3 Mean pressure gradient, mmHg1.37.43.2153.2 RegurgitationnonetrivialmildnonetrivialCT Maximum size of low attenuation area consistent with thrombus, mm8.15.45.26.5Not significant Attenuation, HU106.3108.5113.7110.0Not measurableLeaflet opening angle assessed by cinefluoroscopy On admission, degreestuck, stuckstuck, 58.8stuck, stuckstuck, 58.5stuck, 64.2 After thrombolysis, degree77.9, 81.583.6, 86.080.9, 81.283.2, 82.683.2, 82.2PV, pulmonary valve; TV, tricuspid valve.Fig. 2Imaging findings before and after low-dose thrombolytic therapy (Case 2)(A, B) Doppler echocardiography before thrombolytic therapy showed an elevated peak velocity of 3.3 m/s across the mechanical pulmonary valve (A), which improved to 1.8 m/s after therapy (B). (C, D) Contrast-enhanced CT before therapy demonstrated a hypoattenuated mass between the prosthetic leaflets consistent with valve thrombus (C), which resolved after thrombolytic therapy (D). (E-H) Representative cinefluoroscopic images during systole and diastole are shown. Before therapy, a hemi-stuck valve was observed, with immobilization of the lower leaflet and reduced mobility of the upper leaflet (E, G). After therapy, normalization of leaflet motion was confirmed (F, H).Fig. 3Changes in B-type natriuretic peptide (BNP) before and after low-dose thrombolytic therapy. Individual log BNP values before and after therapy are shown. BNP decreased significantly after therapy. Table 2Imaging Findings of the five patients.Table 2Case 1Case 2Case 3Case 4Case 5Thrombosed valvePVPVTVPVPVModelOn-X #19SJM Regent #19On-X #25/33SJM Regent #21SJM Regent #21Echocardiogram findings at thrombosed valveOn admission Peak Velocity, m/s1.43.31.93.53.5 Peak pressure gradient, mmHg7.744.014.650.048.0 Mean pressure gradient, mmHg3.422.08.629.226.0 Regurgitationtrivialmild-moderatemild-moderatemildmildAfter thrombolysis Peak Velocity, m/s0.81.81.32.61.3 Peak pressure gradient, mmHg2.813.06.8266.3 Mean pressure gradient, mmHg1.37.43.2153.2 RegurgitationnonetrivialmildnonetrivialCT Maximum size of low attenuation area consistent with thrombus, mm8.15.45.26.5Not significant Attenuation, HU106.3108.5113.7110.0Not measurableLeaflet opening angle assessed by cinefluoroscopy On admission, degreestuck, stuckstuck, 58.8stuck, stuckstuck, 58.5stuck, 64.2 After thrombolysis, degree77.9, 81.583.6, 86.080.9, 81.283.2, 82.683.2, 82.2PV, pulmonary valve; TV, tricuspid valve. Imaging Findings of the five patients. PV, pulmonary valve; TV, tricuspid valve. Imaging findings before and after low-dose thrombolytic therapy (Case 2) (A, B) Doppler echocardiography before thrombolytic therapy showed an elevated peak velocity of 3.3 m/s across the mechanical pulmonary valve (A), which improved to 1.8 m/s after therapy (B). (C, D) Contrast-enhanced CT before therapy demonstrated a hypoattenuated mass between the prosthetic leaflets consistent with valve thrombus (C), which resolved after thrombolytic therapy (D). (E-H) Representative cinefluoroscopic images during systole and diastole are shown. Before therapy, a hemi-stuck valve was observed, with immobilization of the lower leaflet and reduced mobility of the upper leaflet (E, G). After therapy, normalization of leaflet motion was confirmed (F, H). Changes in B-type natriuretic peptide (BNP) before and after low-dose thrombolytic therapy. Individual log BNP values before and after therapy are shown. BNP decreased significantly after therapy. Bleeding from the central venous catheter insertion site occurred during thrombolytic therapy in one patient (Case 2). No major bleeding complications or thromboembolic events were observed. The median length of hospital stay was 41 (IQR 28-73) days. All patients were discharged with intensified antithrombotic therapy, including initiation of aspirin and optimization of warfarin therapy. No recurrence of mechanical valve thrombosis was observed during a median follow-up period of 0.7 (IQR 0.3-2.5) years after hospital discharge (Table 3).Table 3Management and Prognosis of the five patients.Table 3Case 1Case 2Case 3Case 4Case 5Days of thrombolytic therapy, d543 + 5a55PT-INR before treatment: after discontinuation of warfarin1.301.041.281.061.05Hospital stay, d22411013444Embolic complicationsNoneNoneNoneNoneNoneMajor BleedingNoneNoneNoneNoneNoneMinor BleedingNoneYesNoneNoneNoneRe-thrombolysisNoneNoneYes→NoneNoneNoneDeathNoneNoneNoneNoneNoneFollow-up duration, y3.70.71.20.30.3aRecurrent thrombosis occurred during a period of inadequate anticoagulation after the initial thrombolytic therapy and resolved after an additional 5-day course of thrombolytic therapy. No further recurrence was observed during follow-up. Table 3Management and Prognosis of the five patients.Table 3Case 1Case 2Case 3Case 4Case 5Days of thrombolytic therapy, d543 + 5a55PT-INR before treatment: after discontinuation of warfarin1.301.041.281.061.05Hospital stay, d22411013444Embolic complicationsNoneNoneNoneNoneNoneMajor BleedingNoneNoneNoneNoneNoneMinor BleedingNoneYesNoneNoneNoneRe-thrombolysisNoneNoneYes→NoneNoneNoneDeathNoneNoneNoneNoneNoneFollow-up duration, y3.70.71.20.30.3aRecurrent thrombosis occurred during a period of inadequate anticoagulation after the initial thrombolytic therapy and resolved after an additional 5-day course of thrombolytic therapy. No further recurrence was observed during follow-up. Management and Prognosis of the five patients. Recurrent thrombosis occurred during a period of inadequate anticoagulation after the initial thrombolytic therapy and resolved after an additional 5-day course of thrombolytic therapy. No further recurrence was observed during follow-up. Discussion In this study, low-dose alteplase restored leaflet mobility in all ACHD patients with right-sided mechanical valve thrombosis without major bleeding. These findings highlight the potential role of thrombolysis as a non-surgical rescue strategy to avoid high-risk reoperation in ACHD. To our knowledge, this is one of the first case series to demonstrate the feasibility of a standardized and reproducible thrombolytic protocol in ACHD. Implications for lifetime management in patients with ACHD Patients with ACHD frequently require repeated interventions for right-sided valvular disease, particularly involving the pulmonary valve and right ventricular outflow tract (RVOT). Surgical repairs in childhood often lead to late valve dysfunction and conduits may become progressively restrictive as patients grow [8,9]. Bioprosthetic valves are commonly selected but have limited durability, with substantial reintervention rates within 10 years, especially in younger patients [10]. Although transcatheter pulmonary valve implantation offers a less invasive option, long-term durability remains uncertain [11]. In this context, the use of durable mechanical valves may represent a rational strategy to reduce repeated interventions in selected patients [12,13]. Thrombus formation as the major drawback of right-sided mechanical valves Right-sided valves are associated with a higher thrombotic risk due to lower flow velocities and increased blood stasis. The incidence of thrombosis has been reported as 1.7% per patient-year for mechanical pulmonary valves, compared with 0–0.6% for mechanical aortic valves [3], with up to 9.6% of patients affected after pulmonary valve replacement [14]. Clinical presentation ranges from incidental findings to life-threatening hemodynamic compromise [6]. Inadequate anticoagulation is the most common cause, with additional contributions from valve-related and patient-related factors [[15], [16], [17]]. In our series, multiple thrombogenic factors-including the low-flow velocity environment of the right heart, subtherapeutic anticoagulation, and severe right ventricular dysfunction-were present. In addition, increased prosthetic valve regurgitation may be a useful clue to prosthetic valve thrombosis, as thrombus can impair both leaflet opening and closure. Dobutamine was used to increase transvalvular flow [18]; however, its effect on thrombolysis remains uncertain, as thrombi formed under high shear stress may be more resistant to fibrinolysis [19]. In Case 1, impaired prosthetic valve leaflet mobility was identified during cardiac catheterization despite a relatively low transvalvular gradient. The prior Glenn procedure may have reduced right ventricular preload and transprosthetic flow, thereby limiting the increase in the transvalvular gradient despite valve thrombosis. In contrast to the other four cases, Case 3 involved a tricuspid mechanical prosthesis and was characterized by more advanced biventricular enlargement and impaired right ventricular function. These characteristics may have provided a distinct low-flow hemodynamic substrate with greater blood stasis, thereby predisposing the patient to prosthetic valve thrombosis. Feasibility and safety of thrombolytic therapy for right-sided mechanical valve thrombosis in adult congenital heart disease A summary of the published studies since 2015 on thrombolytic therapy for right-sided mechanical prosthetic valve thrombosis is provided in Supplementary Table 1. Previous reports have demonstrated favorable outcomes; however, the available evidence remains limited, particularly in patients with ACHD [4,14,15,[20], [21], [22], [23], [24]]. Low-dose, slow-infusion tissue plasminogen activator (t-PA) protocols have improved outcomes in the treatment of mechanical valve thrombosis. In the HATTUSHA study, a low-dose and slow-infusion protocol using t-PA 25 mg administered over 6 h achieved a high success rate of 90.4% in patients with thrombosed aortic, mitral, and tricuspid mechanical valves [4]. However, these studies predominantly included left-sided valves in non-ACHD populations. In contrast, our cohort consisted exclusively of ACHD patients with right-sided mechanical valves. Favorable outcomes have also been reported in patients with mechanical pulmonary valve thrombosis, with success rates approaching 84.6%, supporting thrombolytic therapy as an effective treatment option for right-sided mechanical valves [16]. Accordingly, the 2025 ESC/EACTS guidelines recommend considering thrombolytic therapy in patients with right-sided mechanical valves or those at high surgical risk [5]. In our series, intensified anticoagulation alone was insufficient, and a standardized low-dose alteplase protocol with concomitant dobutamine administration restored leaflet mobility in all patients without major complications. These findings suggest that standardized low-dose thrombolytic therapy may represent a feasible and safe option for managing right-sided mechanical valve thrombosis in ACHD, potentially supporting the use of durable mechanical valves in patients requiring repeated sternotomies. Therefore, optimal management of valve thrombosis is critical in maximizing the long-term benefits of mechanical valves in ACHD. Limitations This study has several limitations. It is a retrospective, single-center study with a small sample size, limiting the generalizability of our findings. Only patients with mechanical valves were included, precluding comparison with bioprosthetic valves and evaluation of repeat interventions. In addition, the optimal PT-INR target for preventing recurrence remains unclear and long-term outcomes could not be fully assessed due to limited follow-up period. Future multicenter prospective studies with larger cohorts are warranted. Conclusion Low-dose alteplase thrombolytic therapy appears to be a feasible and safe treatment for mechanical valve thrombosis in patients with ACHD. This non-invasive therapeutic option may support the use of durable mechanical valves, despite their thrombotic risk. Further studies are required to refine treatment strategies. CRediT authorship contribution statement Naoto Shingu: Writing – original draft, Visualization, Methodology, Investigation, Data curation, Conceptualization. Tomoyasu Suenaga: Writing – review & editing, Supervision, Methodology, Investigation, Data curation, Conceptualization. Ayako Ishikita: Writing – review & editing, Supervision, Methodology, Investigation, Data curation, Conceptualization. Soshun Asakawa: Writing – review & editing, Investigation. Masahiko Umei: Writing – review & editing, Investigation. Akiko Nishizaki: Writing – review & editing, Investigation. Takamori Kakino: Writing – review & editing, Investigation. Ichiro Sakamoto: Writing – review & editing, Investigation. Eiko Terashi: Writing – review & editing, Investigation. Kenichiro Yamamura: Writing – review & editing, Investigation. Tomoki Ushijima: Writing – review & editing, Investigation. Kunihiko Joo: Writing – review & editing, Investigation. Yusuke Ando: Writing – review & editing, Investigation. Hiromichi Sonoda: Writing – review & editing, Investigation. Akira Shiose: Writing – review & editing, Supervision, Project administration. Kohtaro Abe: Writing – review & editing, Supervision, Project administration. Sources of funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.